Literature DB >> 23411479

Expression of thymidine phosphorylase and cyclooxygenase-2 in melanoma.

Alessandro M Minisini1, Gaetano Pascoletti, Donatella Intersimone, Elena Poletto, Pamela Driol, Riccardo Spizzo, Cathryn A Scott, Fabio Puglisi, Gianpiero Fasola, Carla Di Loreto.   

Abstract

Several studies have reported an increase in vascular structures in malignant melanoma. Neovascularization can be enhanced by several factors. Among them, thymidine phosphorylase (TP) and cyclooxygenase-2 (COX-2) have been reported to play a role. The expressions of TP and COX-2 were evaluated trough immunohistochemistry in a series of 78 primary cutaneous melanomas diagnosed between 2000 and 2004. The expressions of TP and COX-2 through mRNA and western blot analysis were also evaluated in several melanoma cell lines. TP expression and COX-2 expression were considered positive in 25 cases (32%) and 22 cases (28.2%), respectively. TP-positive melanomas showed a lower mitotic rate (P=0.008), smaller thickness (P=0.01), and absence of lymphovascular invasion (P=0.04). COX-2-positive melanomas showed a higher mitotic rate (P=0.01) and higher thickness (P=0.03). COX-2 expression was associated with reduced disease-free survival (P=0.01). COX-2-positive cases showed a trend toward reduced survival, whereas TP was not correlated with overall survival. COX-2 expression was detected in four of 11 melanoma cell lines both by mRNA and by western blot analysis. Our data show that TP expression is associated with more favorable prognostic factors (such as thin melanoma, low mitotic count, and absence of lymphovascular invasion), whereas COX-2 expression is associated with poor prognostic factors (thicker melanoma and high mitotic count).
© 2013 Wolters Kluwer Health | Lippincott Williams & Wilkins.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23411479     DOI: 10.1097/CMR.0b013e32835e7734

Source DB:  PubMed          Journal:  Melanoma Res        ISSN: 0960-8931            Impact factor:   3.599


  6 in total

Review 1.  New Insights on COX-2 in Chronic Inflammation Driving Breast Cancer Growth and Metastasis.

Authors:  Honor J Hugo; C Saunders; R G Ramsay; E W Thompson
Journal:  J Mammary Gland Biol Neoplasia       Date:  2015-07-21       Impact factor: 2.673

2.  Antimelanoma Effects of Concomitant Inhibition of SIRT1 and SIRT3 in BrafV600E/PtenNULL Mice.

Authors:  Gagan Chhabra; Chandra K Singh; Glorimar Guzmán-Pérez; Mary A Ndiaye; Kenneth A Iczkowski; Nihal Ahmad
Journal:  J Invest Dermatol       Date:  2021-09-29       Impact factor: 7.590

3.  Demethylation by low-dose 5-aza-2'-deoxycytidine impairs 3D melanoma invasion partially through miR-199a-3p expression revealing the role of this miR in melanoma.

Authors:  Cécile Desjobert; Arnaud Carrier; Audrey Delmas; Diego M Marzese; Antoine Daunay; Florence Busato; Arnaud Pillon; Jörg Tost; Joëlle Riond; Gilles Favre; Chantal Etievant; Paola B Arimondo
Journal:  Clin Epigenetics       Date:  2019-01-16       Impact factor: 6.551

4.  Celecoxib as a Valuable Adjuvant in Cutaneous Melanoma Treated with Trametinib.

Authors:  Diana Valentina Tudor; Ioana Bâldea; Diana Elena Olteanu; Eva Fischer-Fodor; Virag Piroska; Mihai Lupu; Tudor Călinici; Roxana Maria Decea; Gabriela Adriana Filip
Journal:  Int J Mol Sci       Date:  2021-04-22       Impact factor: 5.923

Review 5.  COX-2 as a potential biomarker and therapeutic target in melanoma.

Authors:  Diana Valentina Tudor; Ioana Bâldea; Mihai Lupu; Teodor Kacso; Eniko Kutasi; Andreea Hopârtean; Roland Stretea; Adriana Gabriela Filip
Journal:  Cancer Biol Med       Date:  2020-02-15       Impact factor: 4.248

Review 6.  Lipid metabolic Reprogramming: Role in Melanoma Progression and Therapeutic Perspectives.

Authors:  Laurence Pellerin; Lorry Carrié; Carine Dufau; Laurence Nieto; Bruno Ségui; Thierry Levade; Joëlle Riond; Nathalie Andrieu-Abadie
Journal:  Cancers (Basel)       Date:  2020-10-27       Impact factor: 6.639

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.